

BROOK H. BYERS
2750 SAND HILL ROAD
MENLO PARK, CA 94025
(650) 233-3322

May 28, 2023

Judges of the Prix Galien
Galien Foundation
99 John Street, Suite 2502
New York City, NY 10038

Dear Judge Panel,

I am writing this letter in strong support of HealthRhythms for the Prix Galien Award 2023.

My belief in the importance of their work led to my co-leading their \$11M Seed financing round and being a primary support for their recent \$22M Series A financing. Perhaps a more important “signal” of my commitment and involvement with HealthRhythms is my many hours spent advising, mentoring, coaching, and helping the team on strategy, product vision, corporate partnering, and culture building. HealthRhythms is backed by high quality venture capital firms including GSR Ventures, Owl Capital, and Waterline Ventures as well as strategic investors such as the University of Colorado Health System and Otsuka, all of whom did very deep diligence before becoming involved and support the company, its team, and its future to help patients.

HealthRhythms is led by a very experienced management team who have previously built successful healthcare products and companies to improve the life of patients.

I provide this reference with an extensive background in life sciences venture investing, a field I have been deeply involved with since 1972. My longstanding experience spans the formation of the first venture capital Life Science Practice Group in 1984, involvement with more than 90 new technology-based companies, half of which have already become public, and serving in leadership roles in several prominent biotechnology companies.

I have had the privilege of serving as the founding president and then the chairman of four biotechnology companies incubated out of Kleiner Perkins Caufield & Byers. My broad-based engagement includes serving as chairman for leading companies such as Idec Inc. and Athena Neurosciences and numerous board positions in organizations like Pacific Biosciences, Inc., Foundation Medicine, Inc., and Grail. My extensive experience in this dynamic sector, along with my commitment to fostering innovative technologies, positions me well to evaluate and provide insight into the potential of HealthRhythms.

The value proposition of HealthRhythms' Cue platform is exceptional. Its unique features set it apart from existing solutions in the market. The utilization of the

behavioral vital signs and patient-specific digital biomarkers, achieved through algorithms that exploit physiological and behavioral rhythms, allows for personalized interventions in psychiatric medicine. These features of the Cue platform hold the potential to significantly advance personalized medicine, addressing a substantial unmet need in psychiatric medicine and making it a key market differentiator.

HealthRhythms has backed their innovation with extensive scientific evidence. Co-founder and Chief Scientific Officer, Ellen Frank, has over 475 peer reviewed articles to her name, a large percentage of which undergird HealthRhythms' science and clinical models, making the Cue platform one of the most scientifically supported applications I have come across.

From my perspective, these are some of HealthRhythms' core differentiators:

HealthRhythms' co-founders, Choudhury and Matthews, have pioneered digital phenotyping over the past 15 years using passive detection and analysis of voice, physical activity, and other passively sensed behavioral parameters to enhance our understanding of bipolar disorder, depression, and schizophrenia.

Uniquely, in the crowded world of mental health apps, HealthRhythms was founded on a deep clinical-technical synergy that sits on a rock-solid foundation of more than 40 years clinical and laboratory research carried out by co-founders Frank and Kupfer at the University of Pittsburgh and replicated in laboratories around the world.

In contrast to other approaches in the space that take a 'black box' approach to modeling mental health, looking for signal but without understanding the clinical phenomena, HealthRhythms' hypothesis-driven approach is centered on measuring and understanding the well-established behavioral correlates of mental disorders, including the relationship of sleep-wake and circadian regulation to mental health, indeed, to all of health.

They have evolved an approach that can directly enable privacy-sensitive, continuous, objective and, perhaps most important, clinically interpretable measurement of patients' behavior in their natural environment. Their approach is grounded in a deep understanding of how to design digital experiences that are personally meaningful, clinically grounded, and easily woven into patients' daily life.

The potential impact of the Cue platform on patient care, treatment outcomes, and cost reduction is impressive. By detecting co-morbid depression and anxiety in patients with chronic diseases, the Cue platform holds the promise of improving chronic disease outcomes and reducing care costs. In doing so, the objective measurement offered by Cue can dramatically improve the quality of life of patients.

In my long career in the life sciences and health technology sector, I have rarely encountered an innovation as promising as HealthRhythms' Cue platform. This remarkable startup stands poised at the intersection of mental health, technology, and personalized care, pushing boundaries to shape the future of psychiatric medicine.

Their rapid strides in this regard are fueled by the quality of their world-class team, their robust scientific foundation, and the impressive support they have garnered from elite investors.

For these reasons and more, I firmly believe that HealthRhythms epitomizes the ethos of the Prix Galien Award. I fully endorse them for this honor and am confident that they will continue to push the frontiers of digital health innovation, thereby contributing immensely to the advancement of medical science.

Sincerely yours,

A handwritten signature in black ink, reading "Brook Byers". The signature is fluid and cursive, with the first name "Brook" and last name "Byers" clearly distinguishable.

Brook Byers
Founder and Partner
Kleiner Perkins Caufield & Byers
www.kpcb.com
650.233.3322